BioSpace News Archive

- Funding will also enable the addition of new trial sites to accelerate completion of the Phase 2 clinical trial - Data continues to demonstrate the safety and efficacy of onvansertib as a promising new treatment for patients with KRAS-mutated mCRC [13-May-2020] SAN DIEGO , May 13, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-sta

Quanterix’ Simoa Technology Sets New Standard in Protein Detection New research published in Lab on a Chip demonstrates 100x sensitivity improvement on Simoa; marks significant advancement in sensitivity for industry leading detection platform

- Cancer and COVID-19 Clinical trials expected to commence soon - Designed for anti-cancer treatment & iNKTs are synergistic with Agenus’ checkpoint antibodies - Potential to clear SARS-CoV-2 virus and control harmful inflammation - COVID-19 IND expected to clear shortly [13-May-2020] LEXINGTON, Mass. , May 13, 2020 /PRNewswire/ -

Leiters announced that it has entered into a strategic arrangement with the newly reorganized group purchasing organization affiliate of Comprehensive Pharmacy Services, LLC, Comprehensive Purchasing Alliance, LLC, to be the leading 503B service provider to CPA’s hospital members.

OncoSec Medical Incorporated (Nasdaq:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy medicinal product (ATMP) certificate for chemistry manufacturing controls (CMC) data covering its l

As the world’s supply chain for pharmaceutical drugs comes under increasing scrutiny for safety and quality, Chromatic Technologies Inc. (CTI) has introduced printable thermochromic technology that is free of Bisphenol A, F and S.

Ultragenyx Pharmaceutical Inc. announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus gene therapy for the treatment of ornithine transcarbamylase deficiency.

BridgeBio Pharma, Inc., reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

Arena Pharmaceuticals, Inc. announced that members of its senior management team will participate in two upcoming investor conferences.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported first quarter financial results for the period ending March 31, 2020.